A researcher in an Eli Lilly lab. Courtesy Eli Lilly and Co. The number of analysts agreeing with this consensus is 12. They now have $98.00 target price on the stock. This corresponds to a 13.17% downside from the last closing price.
Advertisement
Zacks upgraded shares of Eli Lilly and (NYSE:LLY) from a hold rating to a buy rating in a research note released on Monday morning, MarketBeat reports. 7 have rated it as a strong buy. 5 analysts have advised hold.
The journal Mayo Clinic Proceedings, where more than 100 cancer doctors made their drug cost plea on Thursday, cited research that showed an escalation in cancer medicine prices by an average of $8,500 a year over the past 15 years. Year-to-Date the stock performance stands at 26.97%.
Eli Lilly and Company (NYSE:LLY) witnessed a decline in the market cap on Tuesday as its shares dropped 2.62% or 2.3 points. In the past six months, there is a change of -1.48% in the total insider ownership. Also, SVP Jeffrey N. Simmons sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $78.08, for a total value of $1,561,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link. After trading began at $83.32 the stock was seen hitting $86.8 as a peak level and $81.5 as the lowest level. The heightened volatility saw the trading volume jump to 12,677,730 shares.
Eli Lilly, for the second quarter of fiscal year 2015 (Q2FY15), has reported adjusted earnings per share (EPS), after excluding one-time costs at $0.9, which represented a rise of a hefty 40.63% YoY, when compared to adjusted EPS of $0.64 per share for the second quarter of FY14. The company has a 52-week high of $90.18.
About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Some of the company’s key products and the animal health business should keep performing well. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries.
Advertisement
Set to be completed in 2016, the expansion will feature an additional 175,000 square feet of working space and is expected to generate up to 130 potential new job openings, yielding a 140 percent increase in the center’s space and 70 percent increase in its staff. The Companys products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. Its products in Late-Stage are Dulaglutide, Empagliflozin, Ramucirumab, Evacetrapib, Necitumumab, Tanezumab, Edivoxetine, Liprotamase and Ramucirumab.
